What is a good ApoB level for men?

The 2019 ESC/EAS guidelines define optimal ApoB as below 65 mg/dL for very high-risk patients (established cardiovascular disease), below 80 mg/dL for high-risk patients (diabetes with organ damage, multiple risk factors), and below 100 mg/dL for most adults in primary prevention. These thresholds reflect the evidence that lower ApoB produces proportionally lower cardiovascular event risk.

What ApoB level is dangerous?

Any ApoB above target for the patient's risk category represents excess atherogenic particle burden. An ApoB above 100 mg/dL in a man with diabetes or prior cardiovascular disease is definitively above target. An ApoB above 130 mg/dL in any adult without treatment reflects substantially elevated particle burden.

The most effective interventions for ApoB reduction are: high-intensity statin therapy (40 to 50 percent reduction), ezetimibe added to statin (additional 20 to 25 percent), PCSK9 inhibitors (additional 50 to 60 percent on top of statin), reduction of refined carbohydrate (reduces VLDL overproduction), and weight loss targeting visceral fat.

What is the difference between LDL and apoB?

LDL cholesterol measures the cholesterol content of low-density lipoprotein particles, while apolipoprotein B measures the particle count directly, as each atherogenic lipoprotein carries exactly one apoB molecule. ApoB is a superior predictor of cardiovascular events because it captures all atherogenic particles including small dense LDL, IDL, and VLDL remnants that LDL-C calculations can miss, particularly in patients with metabolic syndrome or elevated triglycerides.

How low should LDL be for heart disease prevention?

For primary prevention in average-risk adults, guidelines recommend LDL below 100 mg/dL for those with elevated 10-year risk. For secondary prevention in patients with established atherosclerotic cardiovascular disease, the ACC/AHA guidelines recommend LDL below 70 mg/dL and consider below 55 mg/dL in very high-risk patients. The FOURIER and ODYSSEY Outcomes trials demonstrated continued event reduction with LDL levels down to 20-30 mg/dL without safety signal.

The System Gap

What Is a Good ApoB Level? The Targets That Protect Against Heart Disease.

ApoB is the most accurate measure of atherogenic particle burden. A cardiologist explains the ESC/EAS targets for prevention and how to reach them.

Job Mogire, MD, FACP, FACC · Medically reviewed June 14, 2026

ApoB is the direct count of every atherogenic particle in circulation. Each LDL, VLDL, and IDL particle carries exactly one ApoB molecule, which means the number of ApoB molecules in a blood sample is the number of particles capable of crossing an arterial wall and contributing to atherosclerosis. The question “what is a good ApoB level” is, precisely translated, asking: how many atherogenic particles circulating in your blood is safe?

The Mechanism

To understand why ApoB matters more than LDL-C in many clinical situations, you need to understand what atherogenesis actually requires at the cellular level.

An LDL particle does not damage the arterial wall by chemical toxicity. It damages the wall through a sequence of events: the particle crosses the endothelial barrier, becomes trapped and oxidized in the subintimal space, triggers a macrophage response, and is taken up by macrophages that become foam cells, the cellular foundation of atherosclerotic plaque. The rate at which this process advances depends on particle concentration: more particles crossing the endothelium per unit time means more subintimal retention, more oxidized LDL, more macrophage recruitment, and faster plaque accumulation. This is the dose-response relationship that cardiovascular epidemiology and genetics have confirmed repeatedly.

LDL-C measures the total mass of cholesterol carried inside LDL particles. It does not count the particles. This creates a clinically important gap in two common situations.

The first situation is small, dense LDL predominance. A man with metabolic syndrome, characterized by central obesity, insulin resistance, elevated triglycerides, and low HDL, tends to produce more LDL particles with lower cholesterol content per particle. Two men can have identical LDL-C concentrations, but the man with small dense LDL carries more particles for the same cholesterol mass, and those additional particles drive more atherogenesis. His LDL-C does not reveal this. His ApoB does.

The second situation is the presence of elevated VLDL. VLDL particles are atherogenic and each carries one ApoB molecule, but VLDL-cholesterol is not included in LDL-C. A man with a triglyceride level of 300 mg/dL is producing substantial VLDL. His ApoB reflects the total atherogenic particle burden including VLDL; his LDL-C does not. If his LDL is calculated by the Friedewald equation, which estimates LDL-C by subtracting VLDL-C and HDL-C from total cholesterol, the elevated triglycerides actually cause the equation to underestimate LDL-C in some clinical contexts, compounding the problem.

ApoB sidesteps both limitations by counting particles directly, regardless of their size, cholesterol content, or triglyceride-driven complexity. It is measured by immunoturbidimetric assay from a standard blood draw, does not require fasting in most laboratory protocols, and costs approximately $25 to $40 as an add-on to a standard lipid panel at commercial laboratories.

The causal chain from ApoB to atherosclerosis is supported by three independent lines of evidence. Mendelian randomization studies, which use naturally occurring genetic variants that lower LDL production as natural experiments, show that individuals with lifelong slightly lower LDL particle numbers have proportionally lower cardiovascular event rates, and this relationship is linear with no apparent floor effect in the studied range. Observational epidemiology, including the Quebec Cardiovascular Study published by Lamarche and colleagues in 1996, showed that ApoB was a stronger predictor of coronary heart disease risk than LDL-C, non-HDL-C, or the total cholesterol to HDL ratio. And intervention trials using lipid-lowering agents that reduce particle number have consistently produced cardiovascular event reductions proportional to the degree of particle reduction.

What the Evidence Shows

The most clinically applicable framework for ApoB targets comes from the 2019 European Society of Cardiology and European Atherosclerosis Society guidelines on dyslipidemia management, published by Mach and colleagues in the European Heart Journal in 2020. The guidelines define risk-stratified ApoB targets based on the dose-response evidence from the Cholesterol Treatment Trialists (CTT) meta-analysis and its derivatives. (Mach et al., European Heart Journal 2020) 5 / Solid

The CTT meta-analysis, published by the CTT Collaboration in Lancet in 2010, pooled data from 26 randomized statin trials involving 169,138 participants. Each 1 mmol/L reduction in LDL-C reduced the annual rate of major vascular events by approximately 22 percent. Because LDL-C and ApoB are closely correlated in most patient populations (each LDL particle carries one ApoB), this evidence base directly informs ApoB targets.

The ESC/EAS guidelines define three primary risk tiers:

Very high cardiovascular risk encompasses patients with established atherosclerotic cardiovascular disease (prior MI, stroke, peripheral artery disease, or coronary revascularization), type 2 diabetes with target organ damage (nephropathy, retinopathy, or neuropathy) or three or more major risk factors, familial hypercholesterolemia with established cardiovascular disease, chronic kidney disease with eGFR below 30 mL/min/1.73m2, or a calculated 10-year cardiovascular risk above 10 percent by the SCORE equation. The ApoB target for this group is below 65 mg/dL.

High cardiovascular risk encompasses patients with markedly elevated individual risk factors (LDL-C above 190 mg/dL, blood pressure above 180/110 mmHg), type 2 diabetes without target organ damage or with duration above 10 years, moderate CKD with eGFR 30 to 59, or a 10-year SCORE risk of 5 to 10 percent. The ApoB target is below 80 mg/dL.

Moderate cardiovascular risk covers most adults in primary prevention with no major individual risk factor elevations and 10-year SCORE risk below 5 percent. The ApoB target is below 100 mg/dL.

These are targets to be actively achieved through pharmacological and lifestyle intervention, not thresholds where values just below the cutpoint are satisfactory and values just above do not matter.

The FOURIER trial, published in NEJM by Sabatine and colleagues in 2017, enrolled 27,564 patients with established cardiovascular disease already on statin therapy and randomized them to evolocumab (a PCSK9 inhibitor) or placebo. The evolocumab group achieved a median LDL-C of 30 mg/dL (and corresponding ApoB of approximately 40 mg/dL) compared to 92 mg/dL on statin alone. The primary composite cardiovascular endpoint was reduced by 15 percent (hazard ratio 0.85, 95% CI 0.79 to 0.92) over a median follow-up of 2.2 years. Critically, the benefit began within months and there was no documented lower limit below which further reduction ceased to provide benefit.

The ODYSSEY OUTCOMES trial, published in NEJM by Schwartz and colleagues in 2018, enrolled 18,924 patients with recent acute coronary syndrome and randomized them to alirocumab or placebo on background statin therapy. The alirocumab group achieved a median LDL-C of 53 mg/dL, and the primary composite endpoint was reduced by 15 percent (hazard ratio 0.85, 95% CI 0.78 to 0.93) over a median follow-up of 2.8 years. Pre-specified subgroup analysis showed that patients with baseline LDL-C above 100 mg/dL derived the greatest absolute benefit. The trial also showed a mortality benefit in this pre-specified subgroup (hazard ratio 0.71 for all-cause mortality, P = 0.006).

These trials collectively support the principle that for very high-risk patients, ApoB reduction well below 65 mg/dL is safe, effective, and associated with further cardiovascular event reduction. The question of where the lower limit of benefit lies remains open; current data do not establish one.

The discordance between ApoB and LDL-C deserves quantification. A landmark analysis by Sniderman and colleagues, published in Annals of Internal Medicine in 2003, examined 8,983 patients and showed that among individuals with LDL-C below 3.4 mmol/L (approximately 130 mg/dL), those in the highest tertile of ApoB had a cardiovascular event rate approximately three times higher than those in the lowest tertile of ApoB. This is a threefold risk difference at the same LDL-C. The LDL-C alone would not have identified this group as being at elevated risk.

Cardiologist's Note

The case I see most often that illustrates the ApoB-LDL gap: a man in his mid-50s, on atorvastatin 40mg, whose most recent lipid panel shows LDL-C of 70 mg/dL. His physician documents the lipid management as successful. The visit note says “LDL at goal.” He has never had ApoB measured.

When I add ApoB to the panel, it comes back at 90 to 95 mg/dL. At 90 mg/dL, his ApoB is above the ESC/EAS target of 65 mg/dL for a very high-risk patient. The discordance is explained by elevated triglycerides in the 200 to 250 mg/dL range, reflecting VLDL overproduction from visceral adiposity and insulin resistance. His LDL-C is suppressed by the statin, but his particle count, measured directly by ApoB, reflects the additional VLDL contribution that LDL-C does not capture.

The next step in this patient is ezetimibe 10 mg daily. IMPROVE-IT, the major randomized trial of ezetimibe, showed that adding ezetimibe to simvastatin in post-ACS patients reduced the composite cardiovascular endpoint by 6.4 percent relative risk reduction over 7 years compared to simvastatin alone. That may sound modest, but it is the incremental benefit on top of already-effective statin therapy, and it is achieved with a generic drug that costs approximately $10 to $15 per month. In my patient with ApoB of 92 and LDL-C of 70, ezetimibe would be expected to reduce ApoB by an additional 20 to 25 percent from the statin-treated baseline, bringing him to approximately 70 to 72 mg/dL, close to or at target.

The argument I most commonly hear against ordering ApoB is that it is not covered by all insurance plans. My response is that the out-of-pocket cost at a commercial laboratory is roughly $25 to $40. For a patient at high cardiovascular risk, spending $35 to know their actual particle burden is not an unreasonable proposition. The alternative is managing a surrogate marker (LDL-C) that systematically underestimates particle burden in the most common metabolic phenotype encountered in preventive cardiology today.

I also want to be clear about what ApoB cannot tell you. It measures the current flow rate of atherogenic particles in the blood. It does not measure the plaque already deposited in the arterial wall from prior decades of elevated ApoB. A man who has been at ApoB 140 for 20 years and then initiates statin therapy to bring his ApoB to 70 has dramatically slowed the accumulation process, but he already has the plaque that accumulated during those prior two decades. For the anatomical picture of existing plaque burden, coronary calcium scoring and coronary CT angiography are the tools, not ApoB. ApoB and CAC scoring answer different questions and are most powerful when used together.

How the Target Numbers Were Derived: The Trial Evidence Behind 90, 70, and 55 mg/dL

The three-tiered ApoB target system in current guidelines, 90 mg/dL for primary prevention, 70 mg/dL with significant risk factors, 55 mg/dL for established cardiovascular disease, is not convention. Each threshold is anchored to cardiovascular outcomes trial data, and understanding that evidence clarifies what each target represents beyond an abstract number.

The 90 mg/dL primary prevention target reflects ApoB levels associated with low event rates in large epidemiological cohorts including MESA and EPIC-Norfolk, where participants with ApoB below this threshold had substantially lower rates of cardiovascular events over follow-up periods of five to fifteen years. It also approximates the on-treatment ApoB achieved in the JUPITER trial primary prevention arm (Ridker et al., NEJM 2008), where rosuvastatin-treated patients achieved a median LDL-C of 55 mg/dL and ApoB of approximately 80 mg/dL, associated with a 44 percent relative risk reduction for the primary composite endpoint.

The 70 mg/dL intermediate-risk target is most directly supported by IMPROVE-IT (Cannon et al., NEJM 2015), which enrolled 18,144 post-ACS patients and randomized them to ezetimibe plus simvastatin versus simvastatin alone. The combination arm achieved a mean LDL-C of 53.7 mg/dL, corresponding approximately to ApoB in the 60 to 70 mg/dL range, driving a 6.4 percent relative risk reduction in the primary cardiovascular composite at seven years. The message from IMPROVE-IT was that ApoB reduction below 70 mg/dL produces incremental cardiovascular benefit beyond what statin monotherapy achieves. 5 / Solid

The 55 mg/dL very high-risk target derives primarily from the PCSK9 inhibitor outcome trials. In FOURIER, evolocumab reduced median LDL-C to 30 mg/dL (ApoB approximately 40 mg/dL). In ODYSSEY OUTCOMES, alirocumab achieved a median LDL-C of 53 mg/dL. Both trials showed continued incremental benefit at these very low levels, with no identified floor below which further ApoB reduction ceased to protect. The pre-specified analysis in FOURIER also found that patients on longer prior statin treatment derived greater absolute benefit from further reduction, consistent with the interpretation that ongoing ApoB lowering inhibits new plaque deposition while the prior plaque burden determines the baseline event rate.

The consistency across primary prevention, secondary prevention after ACS, and very high-risk populations establishes that ApoB reduction follows a continuous dose-response relationship. A result “below the lab’s reference range” and a result below the clinically derived trial-based target are not the same statement. The lab range is the distribution average. The trial-derived target is the concentration associated with the event rate the trials were designed to achieve.

What to Do This Week

Request ApoB from your physician at your next lipid evaluation if you have never had it measured. It requires the same blood draw as a standard lipid panel. Ask specifically for ApoB to be added to the order; it is not included in a standard lipid panel unless requested. If cost is the concern, most commercial labs process it for $25 to $40.
Identify your risk tier using the ACC/AHA pooled cohort equations (available at tools.acc.org) or the ESC SCORE calculator, then compare your ApoB result to the corresponding target. If you have established cardiovascular disease, type 2 diabetes with organ damage, or CKD stage 3 or above, your target is below 65 mg/dL regardless of what any risk calculator returns. The very high-risk designation applies by condition, not by calculation.
If you are above your ApoB target despite statin therapy, ask about ezetimibe 10 mg daily as the next pharmacological step. It is generic, inexpensive, well-tolerated, and produces an additional 20 to 25 percent ApoB reduction from the statin-treated baseline. IMPROVE-IT demonstrated its incremental cardiovascular benefit on top of statin therapy in a post-ACS population.
If elevated triglycerides are present alongside a high ApoB, address the VLDL-driven component through dietary reduction of refined carbohydrates and simple sugars. This is not a complete solution, but reducing hepatic VLDL production through dietary change can lower ApoB independently of statin effects. The combination of statin, ezetimibe, and dietary VLDL reduction often achieves targets that statin alone cannot.
Follow up with a repeat ApoB 6 to 12 weeks after any medication change or significant dietary intervention to confirm the target has been reached, not just addressed. A single measurement after treatment initiation captures the response but not the sustained achievement. Lipid management requires longitudinal confirmation, not a single check and a chart note.

ApoB is not a new measurement. The assay has been available for decades. What is new is the clarity of the evidence connecting particle count to cardiovascular outcomes and the recognition that LDL-C, for a large fraction of the population at highest risk, is not an adequate proxy for that particle count. The test costs $35 and takes the same blood draw as a cholesterol check. The gap between what it reveals and what a standard lipid panel shows is often the gap between a patient who is undertreated and one who is not.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.

Start with the gap between how you appear and what your body is doing.

Take the Signal Check

Did this land?

The conversation

Join the men working through this in the open.